Possible Involvement of the Vascular Endothelial Growth Factor-Flt-1-Focal Adhesion Kinase Pathway in Chemotaxis and the Cell Proliferation of Osteoclast Precursor Cells in Arthritic Joints

Yoshihiro Matsumoto, Kazuhiro Tanaka, Go Hirata, Masuo Hanada, Shuichi Matsuda, Toshihide Shuto and Yukihide Iwamoto

*J Immunol* 2002; 168:5824-5831; doi: 10.4049/jimmunol.168.11.5824

http://www.jimmunol.org/content/168/11/5824

References

This article cites 42 articles, 21 of which you can access for free at:

http://www.jimmunol.org/content/168/11/5824.full#ref-list-1

Why *The JI*? Submit online.

- **Rapid Reviews! 30 days** from submission to initial decision
- **No Triage!** Every submission reviewed by practicing scientists
- **Fast Publication!** 4 weeks from acceptance to publication

*average

Subscription

Information about subscribing to *The Journal of Immunology* is online at:

http://jimmunol.org/subscription

Permissions

Submit copyright permission requests at:

http://www.aai.org/About/Publications/JI/copyright.html

Email Alerts

Receive free email-alerts when new articles cite this article. Sign up at:

http://jimmunol.org/alerts

*The Journal of Immunology* is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852
Copyright © 2002 by The American Association of Immunologists All rights reserved.
Print ISSN: 0022-1767 Online ISSN: 1550-6606.
Possible Involvement of the Vascular Endothelial Growth Factor-Flt-1-Focal Adhesion Kinase Pathway in Chemotaxis and the Cell Proliferation of Osteoclast Precursor Cells in Arthritic Joints

Yoshihiro Matsumoto, Kazunori Tanaka, Go Hirata, Masuo Hanada, Shuichi Matsuda, Toshihide Shuto, and Yukihide Iwamoto

Vascular endothelial growth factor (VEGF) plays a crucial role in the pathogenesis of inflammatory joint disease, including angiogenesis and synovitis. Recent reports have shown that the development of synovitis, a model of rheumatoid arthritis, in collagen-induced arthritis in mouse, can be attenuated with neutralizing anti-VEGF Ab. This suggests the involvement of VEGF signals in arthritic joint destruction. Additionally, it was demonstrated that VEGF acts as a chemoattractant for OCs and that the invasion of OCs into hypertrophic cartilage requires the presence of VEGF. OC precursors (pOCs) are recruited from hematopoietic tissue, including bone marrow, via circulatory blood. However, the precise process of the recruitment of pOCs into the site of bone resorption remains unclear.

VEGF binds to two tyrosine kinase receptors, Flt-1 and Flk-1, with high affinity (5). While the biological function of the VEGF receptor type II, Flk-1, is understood, that of Flt-1 is still unclear (6). It has been recently reported that VEGF is potentially a monocyte chemoattractant (7) and that monocytes express not Flk-1 but Flt-1 (8). Furthermore, macrophages derived from Flt-1 mutant mice indicated deranged chemotaxis in response to VEGF (9). These findings show that the activation of Flt-1 may stimulate the migration of monocyte/macrophage lineages. However, the signaling pathway of Flt-1 was not yet fully understood.

Focal adhesion kinase (FAK) is a cytoplasmic protein tyrosine kinase that is localized to focal adhesions (10) and involved in the control of several biological processes, including cell spreading, migration, and survival (11). FAK associates with activated growth factor receptors such as platelet-derived growth factor and epidermal growth factor receptors through its N-terminal domain and plays important roles in platelet-derived growth factor-induced and epidermal growth factor-induced cell migration (12). Furthermore, it has been shown that the tubulogenic activity of rat endothelial cells is dependent on the VEGF-Flt-1-FAK pathway (13).

In this study, we tried to elucidate the effects of VEGF on pOCs in vitro and the role of the VEGF signaling pathway in the recruitment of pOCs in rats with adjuvant-induced arthritis (AIA). We demonstrate for the first time the possible involvement of the VEGF-Flt-1-FAK pathway in chemotaxis and the cell proliferation of pOCs in arthritic joint destruction.

Materials and Methods

Agents

Recombinant mouse VEGF was obtained from Genzyme/Technne (Minneapolis, MN). Anti-receptor activators of NF-xB (RANK), VEGF, Flt-1, and Flk-1 Abs were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-FAK and phosphotyrosine (clone 4G10) Abs came from Upstate

Received for publication December 26, 2001. Accepted for publication March 20, 2002.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

© 2002 by The American Association of Immunologists 0022-1767/02/$02.00

Copyright © 2002 by The American Association of Immunologists 0022-1767/02/$02.00

Department of Orthopedic Surgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

Address correspondence and reprint requests to Dr. Yukihide Iwamoto, Department of Orthopedic Surgery, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582. E-mail address: yiwamoto@ortho.med.kyushu-u.ac.jp

Abbreviations used in this paper: VEGF, vascular endothelial growth factor; OC, osteoclast; pOC, OC precursor cell; MCP-1, monocyte chemoattractant protein-1; MAPK, mitogen-activated protein kinase; PI3K, phosphatidylinositol 3-kinease; mit, multiplicity of infection; AIA, adjuvant-induced arthritis; FAK, focal adhesion kinase; RANK, receptor activator of NF-xB; FRNK, FAK-related nonkinase; BrdU, 5-bromo-2’-deoxyuridine; TRTC, tetramethylrhodamine isothiocyanate; TRAP, tartrate-resistant acid phosphatase; Pyk2, proline-rich tyrosine kinase 2.
Biotechnology (Lake Placid, NY). Anti-phospho-FAK and proline-rich tyrosine kinase 2 (Pyk2) Abs were from BioSource (Chicago, IL). A cell proliferation ELISA 5-bromo-2′-deoxyuridine (BrdU) kit was purchased from Roche (Mannheim, Germany). PD98059 was obtained from Calbiochem (San Diego, CA), and wortmannin was purchased from Sigma-Aldrich (St. Louis, MO).

**Induction of AIA**

Induction of AIA was performed as previously described (14). Briefly, 10 to 12-wk-old female Lewis rats (100 g) were injected s.c. with 300 μl (5 mg/ml) of lypoephilized *Mycobacterium butyricum* (Difco, Detroit, MI) at the base of tail. All time points were considered in relation to the AIA induction day, designated as day 0. Arthritis of the bilateral ankle joints was developed in 100% of the treated animals by day 10.

**Immunohistochemistry and immunofluorescence**

Immunohistochemistry and immunofluorescence were performed as previously described (15). Briefly, joint specimens were initially decalcified for 2 wk in an EDTA-containing buffer and embedded in paraffin. The endogenous peroxidase activity was quenched by incubating the sections in absolute methanol and 3% hydrogen peroxide. The slides were then incubated with various primary Abs. Biotinylated Abs and peroxidase-conjugated streptavidin were used as second and third reagents, respectively. The signals were detected using 3-amin-9-ethylcarbazole in N,N-dimethylaniline. The slides were counterstained with methylgreen. For immunofluorescence examination, primary Abs were applied simultaneously and incubated overnight at 4°C. The samples were washed in PBS and incubated with FITC- or tetramethylrhodamine isothiocyanate (TRITC)-conjugated streptavidin as second and third reagents, respectively. The samples were mounted and examined by confocal laser scanning microscopy.

**Cell lines and culture conditions**

The mouse myeloid cell line Raw 264.7 was obtained from American Type Culture Collection (Manassas, VA). The cells were maintained in an anti-MEM (Nissui Pharmaceutical, Tokyo, Japan) supplemented with 100 U/ml penicillin, 100 μg/ml streptomycin, and 1% FBS. The cells were cultured at 37°C in a humidified atmosphere with a CO2 content of 5%. The cells were harvested by scraping, counted using a hemocytometer, and then used for various experiments.

**Immunoprecipitation and immunoblotting**

Cells that were growing logarithmically (2–4 × 10^6) at ~70% confluency were harvested and solubilized in a lysis buffer (20 mM Tris pH 7.4, 250 mM NaCl, 1.0% Nonidet P-40, 1 mM EDTA, 50 mg/ml leupeptin, and 1 mM PMSF). Protein quantity was determined with a Bradford protein assay. The protein samples were boiled for 5 min, and 10 μg of total protein from each sample was run on 4–12% gradient pre-cast MOPS-polyacrylamide gels (NOVEX, San Diego, CA) and blotted onto a nitrocellulose filter. For immunoprecipitation, lysate aliquots were incubated with anti-FAK Ab overnight at 4°C. Immunocomplexes were collected on protein A-G Sepharose beads (Santa Cruz Biotechnology). The beads were washed three times with a lysis buffer, boiled, and subjected toelectrophoresis. After transfer to nitrocellulose membranes, the filters were pre-treated with TBS containing 5% dry milk and 0.05% Triton X for 2 h at room temperature. They were then incubated with the appropriate primary Abs for 2 h at room temperature. After several washes, a HRP-conjugated secondary Ab (BioSource) was added and incubated at room temperature for 1 h. After the final wash, the immunoreactivity of the blots was detected using an ECL system (Amersham, Arlington Heights, IL).

**Cell proliferation assay**

Raw cells seeded in culture plates were incubated in serum-free medium with or without VEGF for 24 h. The cell growth rate was determined using a cell proliferation kit (Roche) based on the ELISA for a thymidine analog, BrdU, according to the manufacturer’s protocol.

**Chemotaxis assay**

The chemotaxis assay was performed using transwell chambers (Costar, Cambridge, MA) as described previously (16–18). In brief, cells were suspended in serum-free anti-MEM containing 1% BSA and seeded in the upper chamber. The lower chamber was filled with serum-free anti-MEM, which was supplemented with various cytokines (10 ng/ml VEGF, 10 ng/ml TNF-α, 500 ìg/ml IL-1α, 10 ng/ml M-CSF, and 10 ng/ml monocyte chemotactant protein-1 (MCP-1)). Polyvinylpyrrolidone-free polycarbonate filters with 8-μm pore size were coated with type IV collagen and inserted between the two chambers. Then the cells were allowed to migrate for 6 h at 37°C. After the incubation, cells that migrated to the lower side of the filter were fixed, stained, and counted for five fields per filter under a microscope.

**Flow cytometry**

Cells were washed with ice-cold PBS twice and harvested by scraping. The cells were then stained with anti-Fit-1 or Fik-1 Abs. The stained cells were further incubated with FITC-conjugated secondary Abs and analyzed using a flow cytometer (FACS Calibur; BD Biosciences, San Jose, CA).

**Adenoviral constructs**

A replication-defective adenovirus encoding FAK-related nonkinase (FRNK), Adv-FRNK, was kindly provided by Dr. A. M. Samarel (19). A replication-defective adenovirus containing the p35 gene (Adv-LacZ), was used to control for the nonspecific effects of viral infection. Adenoviruses were amplified and purified using HEK293 cells, as previously described (20). Preliminarily, it was determined that a viral concentration of ≥10 multiplicity of infection (moi) produced a detectable expression of FRNK protein within 48 h. The infected cells were subjected to immunoblotting, chemotaxis, and cell proliferation assays.

**Assessment of the effect of Adv-FRNK on AIA**

Twenty-one rats were immunized with adjuvant (day 0). On days 7 and 14, PBS (n = 7), LacZ (n = 7), and FRNK (n = 14) were intraperitoneally injected with 50 μl of PBS, adv-LacZ, and adv-FRANK, respectively. The viruses (1 × 10^6 virus particles per joint) were directly injected into the bilateral joint spaces. On days 7, 14, 21, and 28, hind paws were immersed into the chamber up to the anatomic hair line and edema measurement were made with a volumetric apparatus (MK-550; Muromachi-kikai, Tokyo, Japan). On days 21 and 28, the rats were sacrificed and the therapeutic effects of Adv-FRANK injection were examined. For histological examination, the specimens were fixed and decalcified in 10% EDTA for 14 days and embedded in paraffin. The sectioned specimens were subjected to tartrate-resistant acid phosphatase (TRAP) staining and immunohistochemistry. The number of TRAP-positive cells was calculated in three sections of ankle joints from three different specimens in each group. Five visual fields were randomly selected in each section and the number of TRAP-positive cells was counted under a microscope. For radiological examination, both hind paws were dissected on day 28 and examined by soft x-ray (Softex, Tokyo, Japan). The evaluations were performed blindly by the same observer. A 0–3 subjected grading scale (0 = normal, 1 = mild, 2 = moderate, 3 = severe) described previously (21), with modification, was used to evaluate four different parameters including joint space narrowing, subchondral bone erosion, osteoporosis, and periosteal new bone formation. The radiological score refers to the sum of the subjective scores for each of these four parameters (maximum 12).

**Statistical analysis**

The values of chemotaxis and cell proliferation assays were expressed as the mean ± SD and were statistically analyzed by a Student’s t test. The volume of the hind paw volume, the number of TRAP-positive cells, and the radiological scores were analyzed by Mann-Whitney U test.

**Results**

**Expression of VEGF and VEGF receptors at the site of bone destruction in rats with AIA**

Initially, we analyzed the expression profiles of VEGF and VEGF receptors in the specimens taken from the ankle joints of rats with AIA. Arthritis was remarkably induced in the hind feet of the rats ~3 wk after immunization by adjuvants. The specimens of ankle joints showed strong bone destruction and the accumulation of mononuclear (Fig. 1b, arrows) and multinuclear cells (Fig. 1b, arrowheads). TRAP staining demonstrated the presence of bone-resorbing OCs (Fig. 1c, arrowheads). In serial sections, expressions of VEGF and Fli-1 were observed mainly in infiltrating mononuclear cells (Fig. 1, d and e, arrows) and TRAP-positive multinuclear cells (Fig. 1, d and e, arrowheads) that were near the bone surface. Fik-1 expression was not found in the same cells (Fig. 1f). Tissue sections stained with preimmune control IgG showed no nonspecific staining (Fig. 1g). Because mature OCs and pOCs expressed RANK (22), we next investigated whether Fli-1
was colocalized with RANK-positive cells in the AIA joints. The specimens were incubated with anti-RANK (Fig. 1h) and anti-Flt-1 (Fig. 1i) Abs and then reacted with TRITC- or FITC-labeled secondary Abs, respectively. As shown in Fig. 1j, RANK and Flt1 were colocalized in mononuclear (Fig. 1j, arrow) and multinuclear (Fig. 1j, arrowheads) cells in the specimens. These results suggest that OCs and pOCs in the AIA joints expressed Flt-1.

Expression of Flt-1 in Raw cells, a model of pOCs

We next focused on the involvement of VEGF signaling in pOCs in vitro. The myeloid Raw cells in mice have been shown to be able to differentiate into OC-like cells in the presence of RANK ligand (23, 24). In this study, treatment of Raw cells with RANK ligand (100 ng/ml) for 6 days induced the formation of multinuclear TRAP-positive OC-like cells, and the cells were able to form resorption pits on dentin slices (data not shown). Raw cells also expressed CD11b, which is a typical marker of macrophages (data not shown), indicating that Raw cells are in the same lineage as monocyte-macrophage and can be used as pOCs. FACS analysis demonstrated that Raw cells expressed Flt-1, but not Flk-1 (Fig. 2a). Expression of VEGF was also observed in the cells (data not shown). Because tyrosine phosphorylation was required to activate Flt-1, we next examined the tyrosine phosphorylation of Flt-1 in Raw cells after treatment with VEGF. As shown in Fig. 2b, Flt-1 was tyrosine-phosphorylated by VEGF treatment, and the neutralizing Ab against VEGF effectively inhibited the phosphorylation of Flt-1.

Effect of VEGF treatment on chemotaxis and the cell proliferation of Raw cells

Adding VEGF to the lower chamber stimulated the chemotaxis of Raw cells, and maximal stimulation was observed at 10 ng/ml with a typical bell-shaped curve. VEGF-driven chemotaxis was inhibited by the neutralizing Ab to VEGF (Fig. 3a). However, other bone-resorptive cytokines such as TNF-α, IL-1α, and M-CSF could not enhance the chemotaxis of Raw cells. However, the addition of serum or MCP-1 to the lower chamber enhanced the chemotaxis, as previously reported (25) (Fig. 3b). We next analyzed the VEGF-induced cell proliferation of Raw cells by using BrdU incorporation assay. Stimulation of serum-starved Raw cells with various concentrations of VEGF for 24 h raised the cell proliferation dose-dependently in contrast to serum-free control cells (Fig. 3c). VEGF (50 ng/ml) stimulated the cell proliferation of Raw cells at a level ~3-fold higher than that of control cells. TNF-α, IL-1, and M-CSF also stimulated the cell proliferation of Raw cells (Fig. 3d). These results indicate that VEGF enhanced the chemotaxis and cell proliferation of Raw cells.

Tyrosine phosphorylation of FAK induced by VEGF

VEGF binds to its plasma membrane receptors and transmits signals through the phosphorylation of intracellular proteins. After

FIGURE 1. Expression of VEGF and VEGF receptors in arthritic joints. Control normal rats (a) and rats immunized with adjuvant (b–f) were sacrificed on day 21, and serial sections of the ankle joints were prepared. The sections were stained with H&E (a and b), TRAP (c), and Abs against VEGF (d), Flt-1 (e), Flk-1 (f), or control IgG (g). Arrowheads indicate multinuclear cells and arrows indicate surrounding mononuclear cells. Original magnification: ×100. For the immunofluorescence, the serial sections were prepared as above and stained with anti-RANK (h) and anti-Flt-1 (i) Abs, followed by secondary Abs conjugated with TRITC and FITC, respectively. Both images were merged (j). Arrowheads indicate multinuclear cells and arrowheads indicate surrounding mononuclear cells.

FIGURE 2. Expression of Flt-1 in Raw cell models of pOCs. a, Flow cytometric analysis of the expression profiles of VEGF receptor in Raw cells. The cells were reacted with anti-Flt-1 and Flk-1 Abs and then with FITC-conjugated secondary Abs. They were then analyzed using flow cytometry. b, Tyrosine phosphorylation of Flt-1 in response to VEGF. Raw cells were cultured in a serum-free medium overnight and then exposed to various concentrations of VEGF with or without a neutralizing Ab (100 ng/ml) for 10 min. The cell lysates were subjected to SDS-PAGE, and the filters were immunoblotted with anti-tyrosine phosphorylated Flt-1 Abs (upper panel) and anti-Flt-1 Abs (lower panel).
VEGF treatment, major tyrosine-phosphorylated bands were found at 180 to 200 kDa and 110 to 130 kDa in size (data not shown). It was reported that 112-kDa Pyk2, a member of the FAK family, acts to transmit biological signals such as cell adhesion and bone resorption in mature OCS (26). Therefore, we first postulated that VEGF treatment might induce tyrosine phosphorylation of Pyk2. However, Raw cells showed constitutive phosphorylation of Pyk2, and VEGF treatment did not affect the phosphorylation (Fig. 4a).

FAK, a 125-kDa protein, is also reported to be expressed in human peripheral monocytes (27). When Raw cells were stimulated by VEGF (10 ng/ml) for 10 min, the amount of Fli-1 that bound to FAK was increased by ~5- to 6-fold compared with that of the control, suggesting a VEGF-induced association between Fli-1 and FAK (Fig. 4b). We then investigated the effect of VEGF in the tyrosine phosphorylation of FAK. VEGF treatment induced the tyrosine phosphorylation of FAK in Raw cells, and the neutralizing Ab reduced the phosphorylation (Fig. 4c). It has been reported that major sites of FAK phosphorylation are tyrosine residues 397, 576, 577, 861, and 925 (28), and that each residue has a specific function (29). After VEGF stimulation, we observed the tyrosine phosphorylation of Y397 and Y925 (pY397 and pY925) in FAK (Fig. 4d), whereas no tyrosine phosphorylation was observed in Y576, Y577, and Y861 (data not shown). Other cytokines involved in pathological bone resorption, such as IL-1α, TNF-α, and M-CSF, did not induce the phosphorylation of FAK (Fig. 4e). In the joints of rats with AIA, the expressions of pY397 in FAK were also observed in the small mononucleated cells near the bone surface (Fig. 5b, arrows), while control IgG Ab showed no nonspecific staining (Fig. 5c). The expression pattern of pY925 in FAK was similar to that of pY397 (data not shown). Immunofluorescence analysis clearly indicated that small RANK-positive cells, probably pOCS, expressed pY925 in FAK (Fig. 5, d–f, arrows).

Involvement of PI3K and MAPK downstream on the VEGF-Fli-1-FAK pathway

Y397 in FAK has been identified as the binding site for phosphatidylinositol 3-kinases (PI3K) and functions as a critical factor for cell motility (30). In this study, pretreatment of Raw cells with wortmannin, a specific inhibitor of PI3K, reduced VEGF-driven chemotaxis (Fig. 6a), indicating that PI3K might be involved in VEGF-Fli-1-FAK signaling in the cells. Recently it was demonstrated that pY925 in FAK creates a binding site for the SH2 domain of Grb2 (31), and that this interaction may activate the Ras-extracellular signal-regulated kinase/mitogen-activated protein...
kinase (MAPK) pathway (32). In the present study, PD98059, a specific MAPK inhibitor, reduced the VEGF-induced cell proliferation in a dose-dependent manner (Fig. 6b). In the present study, PD98059, a MAPK inhibitor, reduced the VEGF-induced cell proliferation. However, adv-FRNK failed to inhibit the phosphorylation of Y397 and Y925 in FAK (Fig. 6a). The expression of total FAK was not affected by the infection of viruses (data not shown).

Effect of FRNK infection in Raw cells
To further examine the role of FAK in the VEGF-driven chemotaxis and the cell proliferation of Raw cells, we inhibited the function of FAK by using a replication-defective adenovirus which contained FRNK (adv-FRNK). Initially, Raw cells were infected with adenovirus containing β-galactosidase (adv-LacZ). X-gal staining revealed that >95% of the cells were effectively infected with adv-LacZ (moi = 10) (data not shown). When Raw cells were infected with adv-FRNK (moi = 10), the cells expressed FRNK (Fig. 7a). The FRNK-infected cells exhibited a decreased basal level of chemotaxis compared with control cells. Furthermore, the cells expressing FRNK did not respond to VEGF treatment (Fig. 7b). Infection by adv-FRNK also markedly reduced VEGF-induced cell proliferation. However, adv-FRNK failed to inhibit the M-CSF-stimulated proliferation of Raw cells (Fig. 7c). Adv-FRNK also abrogated the phosphorylation of Y397 and Y925 in FAK induced by VEGF (Fig. 7d). The expression of total FAK was not affected by the infection of viruses (data not shown).

Possible involvement of the VEGF-Flt1-FAK pathway in bone destruction in AIA rats
The results described above indicate that the activation of the VEGF-Flt1-FAK pathway may play an important role in infiltrating the pOCs in the arthritic joints of rats with AIA. To obtain direct evidence to support this notion, we injected Adv-FRNK into the inflamed ankle joints of rats with AIA. On day 21, histopathologic examination of the joints from rats treated with adv-FRNK showed suppressed infiltration of mononuclear and multinuclear cells (Fig. 8b) compared with those with adv-LacZ (Fig. 8a). In addition, the number of the mononuclear cells with the expression of pY397 in FAK (Fig. 8d, arrows) was notably reduced through treatment with adv-FRNK, but not with adv-LacZ (Fig. 8c). The serial sections stained with control anti-IgG Ab showed no nonspecific signaling (Fig. 8, e and f). The expression of FRNK proteins in the joints was confirmed 7 days after the injection (Fig. 8g). On days 21–28, the hind paw volume of AIA rats was also decreased by adv-FRNK (Fig. 8h). Injection of adv-FRNK reduced the number of TRAP-positive cells in the arthritic joints found on day 28 (Fig. 8i). Evaluation by radiological scores on day 28 confirmed that the injection of adv-FRNK significantly reduced joint destruction compared with PBS and adv-LacZ injections (Fig. 8j).

Discussion
The osteoclastic bone destruction in inflamed joints is a sequence of pathological conditions; pOCs are recruited to the site of inflammation, then proliferation and, finally, differentiation of OCs occur in
bone where pOCs fuse to form mature OCs under close contact with osteoblasts/stromal cells (33). VEGF, a stimulator of angiogenesis, is known to play a crucial role in the pathogenesis of rheumatoid arthritis by inducing neovascularization in the pannus (34). Recently, it was also shown that VEGF is a potent chemoattractant for monocytes (7) and that pOCs are cells of monocyte/macrophage lineage (33). Therefore, we postulated that VEGF may play an important role in the recruitment of pOCs by promoting their chemoactic activity. In the present study, we found that the immunolocalization of VEGF, Flt-1, and RANK was mainly associated with the infiltrating mononuclear small round cells and polynuclear giant cells in AIA joints, suggesting that the cells are pOCs and mature OCs.

Inflammatory cytokines such as TNF-α, IL-1α, and M-CSF are involved in the progression of bone destruction (35–37). However, the effect of these cytokines on the chemotaxis of pOCs remains unclear. Our data demonstrated that VEGF and MCP-1 stimulated the chemotaxis of Raw cells, whereas TNF-α, IL-1α, and M-CSF did not. Therefore, we concluded that one of the characteristic biological effects of VEGF on pOCs might be the stimulation of chemotaxis in pOCs. Most signals for VEGF-induced cell proliferation of endothelial cells are mediated by Flk-1 (38). In contrast, VEGF treatment caused the phosphorylation of Flt-1 but not Flk-1 and subsequently stimulated the cell proliferation of Raw cells as well as M-CSF, TNF-α, and IL-1α, pointing to a new function of Flt-1 in pOCs.

The kinase activity of FAK is negatively regulated by FRNK via the dephosphorylation of the tyrosine residues of FAK. Adenoviral expression of FRNK effectively inhibited VEGF-induced chemotaxis, cell proliferation, and the tyrosine phosphorylation of FAK in Raw cells. These results directly demonstrate that tyrosine phosphorylation of FAK was required for the biological effects of VEGF in Raw cells. Inflammatory cytokines such as TNF-α, IL-1α, and M-CSF did not stimulate the tyrosine phosphorylation of FAK. Therefore, the results suggest that VEGF specifically causes the tyrosine phosphorylation of FAK via Flt-1 in Raw cells to occur.

It was reported that, in HUVECs, FAK plays an important role in VEGF-induced antiapoptosis (39). Thus, it is reasonable to suppose that the VEGF-Flt-1-FAK pathway may mediate an antiapoptotic signal in Raw cells and that dephosphorylation of FAK by FRNK induces apoptosis of the cells. We first infected Raw cells with adv-FRNK or adv-LacZ (moi = 10) under serum-free conditions with or without VEGF (50 ng/ml) for 24 h. Then cell viability was evaluated by a trypan blue dye exclusion assay. However, cell viability was unchanged by the adv-FRNK infection, and addition of VEGF in the medium did not affect the results. We also conducted a DNA fragmentation assay and confirmed that the adv-FRNK infection did not result in DNA fragmentation (data not shown). As shown in Fig. 6, the MAPK pathway may be involved in the VEGF signaling in Raw cells. Consistent with these findings, FRNK effectively reduced VEGF-induced extracellular signal-regulated kinase activation in the cells (data not shown). Taken together, our results suggest that FRNK exerts its inhibitory effect on cell proliferation by attenuating the MAPK activation but not stimulating apoptosis of the cells.

Immunohistochemistry demonstrated that pY397 in FAK was found mainly in pOCs. Using adv-LacZ, we confirmed that the adenovirus vector can effectively transduce the gene at the site of bone destruction in AIA (data not shown), as previously reported (40). Adv-FRNK injection into the arthritic joints decreased the expression of pY397 in FAK as well as the number of OCs in the specimens, resulting in the reduction of bone destruction. These results suggest that the major targets of adv-FRNK might be pOCs and that adv-FRNK inhibited recruitment and proliferation of pOCs in the inflamed joints. Our present findings support the idea that the VEGF-Flt1-FAK pathway might be involved in the bone destruction associated with AIA. However, in the human monocyte cell line THP-1, integrin-dependent cell adhesion to extracellular matrices such as fibronectin causes a rapid tyrosine phosphorylation of FAK (41). The synovial pannus was rich in fibronectin, which could activate FAK in the...
monocyte/pOCs in the joint (42). Therefore, adv-FRNK may exert its effect by inhibiting the extracellular matrix-integrin-FAK signaling in pOCs, and further investigation is needed to show the direct link between VEGF and FAK in the arthritic joints.

In conclusion, we indicate a linear signal transduction pathway of VEGF in pOCs in arthritic joints; VEGF ligates to its receptor Flt-1, resulting in the tyrosine phosphorylation of FAK, subsequently inducing chemotaxis and cell proliferation as summarized in Fig. 9.

Acknowledgments
We thank Dr. A. M. Samarel for supplying the adenoviral vector expressing Adv-FRNK. We also thank Drs. H. Shimokawa, H. Sakai, A. Matsuo, and M. Tamura for their help with these experiments.

References


